Cosmetic imports: customs release, FDA review and safety evidence are different records

Replace “cleared” with the actual decision

A shipment update that says “cleared” may omit the agency, affected entry lines and conditions. Before using it to plan delivery or answer a retailer, ask for the underlying record. A transport milestone and an agency notice can arrive in the same email thread without meaning the same thing.

This guide describes a recordkeeping and coordination approach for US cosmetic imports. It does not determine admissibility, tariff classification or permission to move a particular shipment. Those decisions require the applicable notices and the responsible importer, broker and advisers. Our proposed workflow keeps the information they need connected.

Customs release concerns entry and custody

FDA describes customs brokers as licensed parties that prepare and file customs entries, arrange duty payment and take steps toward release from CBP custody. FDA-regulated goods also enter an FDA review process. Having a broker coordinate both does not merge the two agencies’ decisions. FDA’s entry-submission explanation.

For goods including cosmetics imported under section 801(a), 19 CFR 141.113(c) treats release from CBP custody as conditional and describes how that period ends or can be extended. Therefore, possession of the goods is not a substitute for checking the applicable FDA status and instructions. 19 CFR 141.113(c).

Operationally, keep the customs entry reference, agency notices and movement instructions distinct from the carrier’s delivery updates. Ask the broker to identify exactly which record supports the next planned action. If a warehouse receives the goods, its receipt should not automatically become the internal signal that every regulatory or quality question is closed.

What FDA “May Proceed” and “Release” mean

FDA’s Regulatory Procedures Manual distinguishes “May Proceed” without FDA examination from “Release” following examination. Its explanations say that neither message provides assurance of compliance with all applicable provisions or prevents later action if a violation is found. Preserve that distinction rather than treating both as a product approval. FDA import procedures, Chapter 9.

The useful internal status is the agency’s actual language, attached to the relevant entry and line. Add the notice date, source and any conditions without replacing the original. A simplified dashboard may help people scan the shipment, but it should lead back to the exact communication.

FDA’s current entry-review page explains that electronic data is screened and that entries not released by the system go to human review. Incomplete information is one possible reason for further review; it is not the only reason. Do not assume that every hold is caused by a paperwork typo. FDA’s entry-review process.

Safety substantiation remains a product obligation

The responsible person’s obligation to maintain supporting safety-substantiation records is separate from an entry status. 21 USC 364d. For the underlying evidence framework, see our MoCRA safety-substantiation guide.

This distinction changes what you send in response to later questions. If a buyer asks for product evidence, a past border notice explains a shipment event. It does not by itself explain which formula was assessed, which studies apply or what a qualified reviewer concluded. Those questions need the relevant product record.

Conversely, a substantial safety file does not settle every import issue. A request about entry declarations, labeling or another stated charge should be addressed on its own terms. Organize evidence around the question being decided, then identify any connection to the wider product file.

Connect the entry line to the product actually shipped

FDA’s cosmetics-import page identifies declared manufacturer, importer or consignee, product description and other entry information as inputs to review. Keep the manufacturer’s actual identity distinct from a trading company or seller name when preparing the information for the entry filer. FDA’s cosmetics-import overview.

Our recommended internal mapping starts with the entry and line, then connects them to the invoice item, commercial SKU and shipment’s identified lot or lots. Where relevant, link the formula, package and label versions through the production records. Mark any relationship that has not yet been confirmed.

The purpose is retrieval, not creating a new mandatory import dossier. An invoice may describe a commercial transaction without carrying every technical identifier the brand uses. Obtain the missing relationship from the supplier’s dispatch or manufacturing records rather than rewriting the invoice to suggest it originally contained more information.

If several lots share an entry line, preserve that one-to-many relationship. If one lot is split across shipments, preserve each shipment connection. This lets a later request reach the right evidence without assuming that one shipment always means one product or one batch.

A hypothetical container with two lotion lots

Imagine a brand importing two lots of the same lotion. The commercial invoice uses one line for the product, while the manufacturer’s packing record identifies two lot codes in separate carton ranges. A logistics update says the container has been released. This is a hypothetical example, not a report of an actual import event.

The coordinator asks the broker for the CBP and FDA records and checks the affected entry lines. The warehouse receives instructions based on those records, not on the shorthand message alone. The product evidence file separately retains the review information and any outstanding lot-related questions.

Later, a buyer asks about one lot. The brand can connect the buyer’s lot reference to the carton allocation, entry line and appropriate evidence. It does not use the container’s release status to answer the buyer’s technical question, and it does not forward a result from the other lot just because both arrived together.

This example illustrates the benefit of precise links: different people can answer transport, entry and product questions without asserting that their own record resolves every other team’s responsibility.

For a detention, organize the response around the charge

FDA explains that a detention notice identifies the apparent violations and a respond-by date. The responsible parties can submit evidence to address the appearance of a violation or request an appropriate reconditioning process. Start with that notice and its named contact; do not substitute a general internet deadline or a generic document bundle. FDA’s detention and hearing guidance.

Our proposed response worksheet has one line per issue: exact charge, affected entry line, relevant product or lot, question to resolve, evidence holder, reviewer and expected output. The importer and advisers determine the response. The coordinator makes sure that the requested evidence can be traced to the goods at issue.

A labeling question and an analytical question may require different work. Describe the difference before asking a laboratory for new testing. If an issuer correction or identity clarification is sufficient to answer a factual discrepancy, pursue that specific output. If substantive evidence is missing, keep it visible and route it to the appropriate specialist.

When an import alert is involved, FDA advises checking the alert’s guidance for information on securing release of an individual shipment. An individual-shipment response and a request for removal from an import alert are distinct matters. Do not assume that resolving one automatically resolves the other. FDA’s import-alert FAQs.

Give the broker a focused evidence handoff

Agree who receives agency notices, who decides the response, who can contact the manufacturer or laboratory, and who submits the authorized materials. An operations coordinator may assemble the records without being the person authorized to represent the importer. Make that ownership clear before a deadline approaches.

For an evidence request, send the source notice, a short description of the issue, the product and lot identifiers, and the precise materials needed from each record holder. Identify what is still missing. Keep translations linked to the originals and distinguish the translator’s work from statements issued by the manufacturer or laboratory.

Preserve the exact response set and its transmission reference. If a corrected file arrives afterward, document whether and how it was provided to the recipient. The history should show what was considered at each stage, rather than presenting a constantly changing folder as if every version had already been submitted.

Keep the warehouse informed without overstating the status

FDA’s examination guidance includes statuses that can apply to all lines or designated lines and describes holding instructions associated with examination or sampling. It also explains that failure to hold goods as directed can lead to a redelivery demand. Use the actual notice to coordinate handling. FDA’s examination and sample-collection guidance.

Our recommended receiving record shows the warehouse reference, identified lots, quantities, applicable handling instruction and the source of any change to that instruction. Avoid a single “approved” field that combines physical receipt, agency status and internal quality disposition. Each can be recorded separately with its responsible person.

For the relationships between product versions and historical evidence, see our cosmetic version-control guide. BeautyAssured helps brands organize product evidence and supplier follow-up around specific questions. Customs and agency decisions, movement instructions and scientific judgments remain with the responsible parties.